Clinton E. Leysath

1.3k citations

20 papers · 1.0k indexed · h-index 16

Impact in

Hematology top 5%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
Biotechnology top 5%

Papers in ⓘ

Biotechnology 6
- Microbial Inactivation Methods 4
- Transgenic Plants and Applications 2
Hematology 3
- Acute Myeloid Leukemia Research 2

Co-authors: Stephen H. Leppla (11 shared papers)Michael Andreeff (4 shared papers)Marina Konopleva (4 shared papers)Kavita Singh (1 shared paper)Zonglin Hu (1 shared paper)David N. Garboczi (1 shared paper)Zeev Estrov (2 shared papers)Charles B. Shoemaker (3 shared papers)
Journals: Journal of Biological Chemistry (3 papers)Infection and Immunity (2 papers)PLoS ONE (2 papers)Blood (2 papers)Analytical and Bioanalytical Chemistry (1 paper)
Partner nations: United States South Korea New Zealand

In The Last Decade

Clinton E. Leysath

20 papers receiving 1.0k citations

Peers

Countries citing papers authored by Clinton E. Leysath

Since Specialization

Citations

This map shows the geographic impact of Clinton E. Leysath's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clinton E. Leysath with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clinton E. Leysath more than expected).

Fields of papers citing papers by Clinton E. Leysath

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Clinton E. Leysath. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clinton E. Leysath. The network helps show where Clinton E. Leysath may publish in the future.

Co-authors

The 25 scholars most cited alongside Clinton E. Leysath, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Clinton E. Leysath Line = papers co-authored together Clinton E. Leysath links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia Blood ·Marina Konopleva, Twee Tsao, Peter P. Ruvolo, Irina Stiouf, Zeev Estrov, Clinton E. Leysath, Shourong Zhao, David Harris, Shirong Chang, C. Ellen Jackson, Mark F. Munsell, Nanjoo Suh, Gordon W. Gribble, Tadashi Honda, W. Stratford May, Michael B. Sporn, Michael Andreeff	2002	157
2	CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells Molecular Cancer Therapeutics ·Linhua Jin, Yoko Tabe, Sergej Konoplev, Yuanyuan Xu, Clinton E. Leysath, Hongbo Lu, Shinya Kimura, Akimichi Ohsaka, Mary-Beth Rios, L Calvert, Hagop M. Kantarjian, Michael Andreeff, Marina Konopleva	2008	151
3	The sub‐nanomolar binding of DNA–RNA hybrids by the single‐chain Fv fragment of antibody S9.6 Journal of Molecular Recognition ·Damilola D. Phillips, David N. Garboczi, Kavita Singh, Zonglin Hu, Stephen H. Leppla, Clinton E. Leysath	2013	122
4	Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia Blood ·Michèle Milella, Zeev Estrov, Steven M. Kornblau, Bing Z. Carter, Marina Konopleva, Ana M. Tari, Wendy Schober, David Harris, Clinton E. Leysath, Gabriel Lopez‐Berestein, Ziwei Huang, Michael Andreeff	2002	100
5	A Single VHH-Based Toxin-Neutralizing Agent and an Effector Antibody Protect Mice against Challenge with Shiga Toxins 1 and 2 Infection and Immunity ·Jacqueline M. Tremblay, Jean Mukherjee, Clinton E. Leysath, Michelle Debatis, Kwasi Ofori, Karen Baldwin, Courtney Boucher, R.L. Peters, Gillian Beamer, Abhineet S. Sheoran, Daniela Bedenice, Saul Tzipori, Charles B. Shoemaker	2013	76
6	A Novel Strategy for Development of Recombinant Antitoxin Therapeutics Tested in a Mouse Botulism Model PLoS ONE ·Jean Mukherjee, Jacqueline M. Tremblay, Clinton E. Leysath, Kwasi Ofori, Karen Baldwin, Xiaochuan Feng, Daniela Bedenice, Robert Webb, Patrick M. Wright, Leonard A. Smith, Saul Tzipori, Charles B. Shoemaker	2012	73
7	Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD86 (B7-2) The Journal of Immunology ·Phillip A. Morton, X T Fu, James A. Stewart, K S Giacoletto, S L White, Clinton E. Leysath, R J Evans, James J. Shieh, Robert W. Karr	1996	67
8	Engraftment of Acute Myeloid Leukemia in NOD/SCID Mice Is Independent of CXCR4 and Predicts Poor Patient Survival Stem Cells ·Giuseppe Monaco, Marina Konopleva, Mark F. Munsell, Clinton E. Leysath, Ruiyu Wang, C. Ellen Jackson, Martin Körbling, Elihu H. Estey, John W. Belmont, Michael Andreeff	2004	38
9	Engineering Anthrax Toxin Variants That Exclusively Form Octamers and Their Application to Targeting Tumors Journal of Biological Chemistry ·Damilola D. Phillips, Rasem Fattah, Devorah Crown, Yi Zhang, Shihui Liu, Mahtab Moayeri, Elizabeth R. Fischer, Bryan Hansen, Rodolfo Ghirlando, Ekaterina M. Nestorovich, Alexander N. Wein, Lacy M. Simons, Stephen H. Leppla, Clinton E. Leysath	2013	32
10	A Heterodimer of a VHH (Variable Domains of Camelid Heavy Chain-only) Antibody That Inhibits Anthrax Toxin Cell Binding Linked to a VHH Antibody That Blocks Oligomer Formation Is Highly Protective in an Anthrax Spore Challenge Model Journal of Biological Chemistry ·Mahtab Moayeri, Clinton E. Leysath, Jacqueline M. Tremblay, Catherine E. Vrentas, Devorah Crown, Stephen H. Leppla, Charles B. Shoemaker	2015	32
11	Crystal Structure of the Engineered Neutralizing Antibody M18 Complexed to Domain 4 of the Anthrax Protective Antigen Journal of Molecular Biology ·Clinton E. Leysath, A.F. Monzingo, Jennifer A. Maynard, J. Barnett, George Georgiou, Brent L. Iverson, Jon D. Robertus	2009	29
12	Engineering antibody fragments to fold in the absence of disulfide bonds Protein Science ·Min Jeong Seo, Ki Jun Jeong, Clinton E. Leysath, Andrew D. Ellington, Brent L. Iverson, George Georgiou	2009	24
13	Cytolethal distending toxin B as a cell-killing component of tumor-targeted anthrax toxin fusion proteins Cell Death and Disease ·Christopher Bachran, Radka Hasikova, Clinton E. Leysath, Inka Sastalla, Y Zhang, Rasem Fattah, Shihui Liu, Stephen H. Leppla	2014	24
14	Mouse Monoclonal Antibodies to Anthrax Edema Factor Protect against Infection Infection and Immunity ·Clinton E. Leysath, Kuang‐Hua Chen, Mahtab Moayeri, Devorah Crown, Rasem Fattah, Zhaochun Chen, Suman R. Das, Robert H. Purcell, Stephen H. Leppla	2011	21
15	Anthrax Toxin Protective Antigen Variants That Selectively Utilize either the CMG2 or TEM8 Receptors for Cellular Uptake and Tumor Targeting Journal of Biological Chemistry ·Kuang‐Hua Chen, Shihui Liu, Clinton E. Leysath, Sharmina Miller-Randolph, Yi Zhang, Rasem Fattah, Thomas Bugge, Stephen H. Leppla	2016	17
16	Small-Molecule Inhibitors of Lethal Factor Protease Activity Protect against Anthrax Infection Antimicrobial Agents and Chemotherapy ·Mahtab Moayeri, Devorah Crown, Guan‐Sheng Jiao, Seong Jin Kim, A. T. Charlie Johnson, Clinton E. Leysath, Stephen H. Leppla	2013	17
17	Anthrax toxin-neutralizing antibody reconfigures the protective antigen heptamer into a supercomplex Proceedings of the National Academy of Sciences ·Mazdak Radjainia, Jaekyung Hyun, Clinton E. Leysath, Stephen H. Leppla, Alok K. Mitra	2010	14
18	Reductive Methylation and Mutation of an Anthrax Toxin Fusion Protein Modulates its Stability and Cytotoxicity Scientific Reports ·Christopher Bachran, P. K. Gupta, Silke Bachran, Clinton E. Leysath, Benjamin Hoover, Rasem Fattah, Stephen H. Leppla	2014	11
19	Anthrax Edema Factor Toxicity Is Strongly Mediated by the N-end Rule PLoS ONE ·Clinton E. Leysath, Damilola D. Phillips, Devorah Crown, Rasem Fattah, Mahtab Moayeri, Stephen H. Leppla	2013	11
20	Zeptomole per milliliter detection and quantification of edema factor in plasma by LC-MS/MS yields insights into toxemia and the progression of inhalation anthrax Analytical and Bioanalytical Chemistry ·Renato C. Lins, Anne E. Boyer, Zsuzsanna Kuklenyik, Adrian R. Woolfitt, Jason Goldstein, Alex R. Hoffmaster, Maribel Gallegos-Candela, Clinton E. Leysath, Zhaochun Chen, Judith O. Brumlow, Conrad P. Quinn, Dennis A. Bagarozzi, Stephen H. Leppla, John R. Barr	2019	10

About Clinton E. Leysath

Clinton E. Leysath is a scholar working on Biotechnology, Hematology, Molecular Biology, Ecology and Genetics, having authored 20 papers that have together received 1.0k indexed citations. Recurring topics across this work include Bacillus and Francisella bacterial research (11 papers), Bacterial Genetics and Biotechnology (6 papers), Bacteriophages and microbial interactions (6 papers), Microbial Inactivation Methods (4 papers), Monoclonal and Polyclonal Antibodies Research (3 papers), Transgenic Plants and Applications (2 papers), Acute Myeloid Leukemia Research (2 papers) and Glycosylation and Glycoproteins Research (2 papers). The work is most often cited by research in Hematology (200 citations), Biotechnology (104 citations), Endocrinology (59 citations), Immunology (227 citations) and Genetics (97 citations). Clinton E. Leysath has collaborated with scholars based in United States, South Korea and New Zealand. Frequent co-authors include Stephen H. Leppla, Michael Andreeff, Marina Konopleva, Kavita Singh, Zonglin Hu, David N. Garboczi, Zeev Estrov, Charles B. Shoemaker, Jacqueline M. Tremblay and Rasem Fattah. Their work appears in journals such as Journal of Biological Chemistry, Infection and Immunity, PLoS ONE, Blood and Analytical and Bioanalytical Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact